Application of a telomerase-based circulating tumor cell (CTC) assay in bladder cancer patients receiving postoperative radiation therapy

Ju, Melody; Kao, Gary D.; Steinmetz, David; Chandrasekaran, S.; Keefe, Stephen Michael; Guzzo, Thomas J.; Christodouleas, John P.; Hahn, Stephen M.; Dorsey, Jay F.

doi:10.4161/cbt.28412

Cited by 23 publications

(18 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CTCs can be assessed to detect the presence of these markers and aid in the diagnosis of the malignancy. [114,115] Alonso-Alconada et al [41] have done molecular profi ling of CTCs isolated from metastatic endometrial carcinoma (EC) patients. They have shown that there is an overexpression of stem cell related genes, i.e.…”

Section: Ctcs In Other Cancers Diagnosis and Treatmentmentioning

confidence: 99%

Role of circulating tumor cells in future diagnosis and therapy of cancer

Potdar¹,

Lotey²

2015

J Cancer Metastasis Treat

View full text Add to dashboard Cite

Circulating tumor cells (CTCs) have become a blistering topic of discussion for oncologists because of their tremendous potential in the diagnosis and treatment of cancer. Over the past few years, they have been doled with quite an amount of research in this area understanding that CTCs are shed from tumors and circulate in the bloodstream. This process can also occur at an early stage of cancer. The major limitation in isolation of CTCs is their availability in limited numbers. Hence, many techniques have been developed and are under continuous improvement to enhance their effi cacy of CTC isolation and enumeration. They have shown their potentiality to not just indicate the presence of a tumor but also to provide us with its core information. They have also proven to be useful in detecting minor subgroups of cells present in the primary tissue which might eventually be the cause of treatment resistance or relapse of the disease. Hence, detecting and characterizing CTCs can defi nitely become an inevitable step in treating solid tumor malignancies. In this review, we have tried to comprehend the basics of CTCs including isolation, detection, characterization, and molecular mechanism of their circulation in the blood stream. We have mostly focused on the signifi cance of CTCs in diagnosis and therapies of four most common types of cancers, namely, breast, prostate, lung, and colorectal. This review provides the coverage of most of the advancements with regards to different tumor malignancies and their probable use in predicting outcomes of the disease to realize the concept of personalized medicine.

show abstract

Section: Ctcs In Other Cancers Diagnosis and Treatmentmentioning

confidence: 99%

Role of circulating tumor cells in future diagnosis and therapy of cancer

Potdar¹,

Lotey²

2015

J Cancer Metastasis Treat

View full text Add to dashboard Cite

show abstract

“…The CTC assay has been described previously for patients with breast cancer, glioma, and bladder cancer. [25][26][27][28][29] Briefly, the probe used in the assay consists of the human telomerase reverse transcriptase (hTERT) promoter element, which drives the expression of adenoviral early region 1A (E1A) and E1B genes, in addition to a cytomegalovirus promoter, which drives GFP expression. The preclinical validation process included studies presented in this article (Figs.…”

Section: Description Of the Assay And Pilot Trialmentioning

confidence: 99%

Tracking viable circulating tumor cells (CTCs) in the peripheral blood of non–small cell lung cancer (NSCLC) patients undergoing definitive radiation therapy: Pilot study results

Dorsey

Kao

MacArthur

et al. 2014

Cancer

Self Cite

View full text Add to dashboard Cite

Background Assays identifying circulating tumor cells (CTC) allow noninvasive and sequential monitoring of the status of primary or metastatic tumors, potentially yielding clinically useful information. However, the effect of radiation therapy (RT) on CTC in patients with non-small cell lung cancer (NSCLC) to our knowledge has not been previously explored. Methods We describe here results of a pilot study of 30 NSCLC patients undergoing RT, from whom peripheral blood samples were assayed for CTC via an assay that identifies live cells, via an adenoviral probe that detects the elevated telomerase activity present in almost all cancer cells but not normal cells, and with validity of the assay confirmed with secondary tumor-specific markers. Patients were assayed prior to initiation of radiation (Pre-RT), during the RT treatment course, and/or after completion of radiation (Post-RT). Results The assay successfully detected CTC in the majority of patients, including 65% of patients prior to start of RT, and in patients with both EGFR wild type and mutation-positive tumors. Median counts in patients Pre-RT were 9.1 CTC/mL (range: undetectable - 571), significantly higher than the average Post-RT count of 0.6 CTC/mL (range: undetectable - 1.8) (p < 0.001). Sequential CTC counts were available in a subset of patients and demonstrated decreases after RT, except for a patient who subsequently developed distant failure. Conclusions These pilot data suggest that CTC counts appear to reflect response to RT for patients with localized NSCLC. Based on these promising results, we have launched a more comprehensive and detailed clinical trial.

show abstract

“…Generally, the filtration system consists of a filtration tube containing the membrane, a manifold vacuum plate with valve settings, a vacuum manifold and a vacuum pump [109][110][111]. Following filtration, CTCs can be stained by standard immuhistochemistry techniques to identify specific proteins or nucleic acid can be extracted and analyzed by ddPCR or NGS to identify mutations [107,[112][113][114]. Oh and coworkers used a high-density microporous chip filter to enrich CTCs and evaluate its clinical utility in colorectal cancer.…”

Section: Methods To Isolate and Identify Ctcmentioning

confidence: 99%

Liquid biopsy - emergence of a new era in personalized cancer care

2018

View full text Add to dashboard Cite

The most successful treatment for cancer involves identifying druggable, biological markers for targeted therapy. In the clinical setting, surgical removal of tumors is the only procedure for identifying such targetable molecules. Shed from tumor cells, these markers are also present in circulating blood, albeit in very negligible amounts. Liquid biopsy is a procedure performed on a blood sample to look for such circulating cancer markers cells or pieces of nucleic acid from the tumor. The procedure shows promise in revolutionizing personalized cancer treatments. Here we briefly review the technique, characterization, and its utilization in clinics.

show abstract

Application of a telomerase-based circulating tumor cell (CTC) assay in bladder cancer patients receiving postoperative radiation therapy

Cited by 23 publications

References 24 publications

Role of circulating tumor cells in future diagnosis and therapy of cancer

Role of circulating tumor cells in future diagnosis and therapy of cancer

Tracking viable circulating tumor cells (CTCs) in the peripheral blood of non–small cell lung cancer (NSCLC) patients undergoing definitive radiation therapy: Pilot study results

Liquid biopsy - emergence of a new era in personalized cancer care

Contact Info

Product

Resources

About